Lifeward Ltd. (LFWD) Earnings Call Transcripts

Lifeward Ltd.'s Latest Earnings Call - Q1 FY2026

Lifeward Ltd. reported its Q1 2026 earnings, highlighting a strategic acquisition and operational challenges. Revenue declined to $3.9 million from $5 million YoY, primarily due to supply chain disruptions affecting AlterG shipments. However, ReWalk personal exoskeleton sales grew by 11% YoY. The acquisition of Oratech, providing access to a protein oral delivery platform, is expected to bolster future growth. Management maintained guidance for 2026 revenue to be similar to 2025, despite a challenging first quarter.

Reported metrics

Guidance from management

Management maintained guidance for 2026 revenue to be similar to 2025, despite a lower first quarter, indicating expected recovery in subsequent quarters.

What management said

Thank you, Drew, and thanks, everyone, who has joined us on the call today. My name is Almog Adar, I'm Lifeward' Chief Financial Officer. And with me on today's call is our President and Chief Executive Officer, Mark Grant. Earlier this morning, Lifeward issued a press release detailing the financial results for the first quarter ended March 31, 2026. I would ask you to review the full text of our forward-looking st...

I think some of the things that most people don't appreciate, and we probably didn't explain well is we had a manufacturing move from Fremont to Massachusetts. We also had a complete facility move within Massachusetts, and we started a contract manufacturer all at the same time. And so all of these things led, with our cash constraints, to timing issues on everything. I would expect that we have similar to last year....

What analysts pressed on

Analysts expressed concerns about the timing of AlterG shipments and the impact of supply chain issues on future quarters. Questions also focused on the gross margin decline and the company's ability to manage resources amidst multiple strategic initiatives.

Main topics on the call

• Oratech Acquisition — Lifeward completed the acquisition of Oratech, gaining access to a protein oral delivery platform. Management stated, 'This transaction significantly strengthens Lifeward's position as a diversified biomedical innovation...
• Revenue Decline — Revenue for Q1 2026 was $3.9 million, down from $5 million in Q1 2025. The decline was attributed to 'temporary supply chain and sourcing constraints associated with working capital limitations.'
• ReWalk Sales Growth — ReWalk personal exoskeleton sales increased 11% YoY to $1.6 million, driven by 'continued progress in reimbursement coverage, channel expansion and international sales.'
• Gross Margin Decline — Gross margin decreased to 34.2% from 42.2% YoY, impacted by 'lower manufacturing absorption, higher freight and tariff expenses, and unfavorable foreign currency exchange rate movements.'

Read the full Lifeward Ltd. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 28 Lifeward Ltd. earnings call transcripts on record, spanning February 20, 2020 to May 15, 2026. Based on this history, Lifeward Ltd. reports quarterly. The most recent call on file is dated May 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

LFWD

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

28

First call

February 20, 2020

Most recent

May 15, 2026

Reporting cadence

quarterly